XML 28 R14.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Goodwill and Intangible Assets | 9 Months Ended
--- | ---
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets | 6. Goodwill and Intangible Assets. The change in the carrying amount of goodwill for the nine-month period ended September 30, 2022 is detailed as follows (in thousands): ​
​ | ​ | ​ | ​
​ |  | 2022
Goodwill balance at January 1 | ​ | $ | 361,741
Effect of foreign exchange | ​ |  | (3,685)
Goodwill balance at September 30 | ​ | $ | 358,056
​ Total accumulated goodwill impairment losses aggregated $8.3 million as of September 30, 2022 and December 31, 2021. We did not have any goodwill impairments for the nine-month periods ended September 30, 2022 and 2021. The total goodwill balances as of September 30, 2022 and December 31, 2021 were related to our cardiovascular segment. ​ Other intangible assets at September 30, 2022 and December 31, 2021 consisted of the following (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, 2022
​ | ​ | Gross Carrying | ​ | Accumulated | ​ | Net Carrying
​ |  | Amount |  | Amortization |  | Amount
Patents | ​ | $ | 28,179 | ​ | $ | (9,724) | ​ | $ | 18,455
Distribution agreements | ​ |  | 3,250 | ​ |  | (2,664) | ​ |  | 586
License agreements | ​ |  | 11,029 | ​ |  | (6,967) | ​ |  | 4,062
Trademarks | ​ |  | 30,194 | ​ |  | (17,189) | ​ |  | 13,005
Customer lists | ​ |  | 34,481 | ​ |  | (31,764) | ​ |  | 2,717
Total | ​ | $ | 107,133 | ​ | $ | (68,308) | ​ | $ | 38,825
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2021
​ | ​ | Gross Carrying | ​ | Accumulated | ​ | Net Carrying
​ |  | Amount |  | Amortization |  | Amount
Patents | ​ | $ | 26,349 | ​ | $ | (8,315) | ​ | $ | 18,034
Distribution agreements | ​ |  | 3,250 | ​ |  | (2,519) | ​ |  | 731
License agreements | ​ |  | 12,663 | ​ |  | (7,768) | ​ |  | 4,895
Trademarks | ​ |  | 30,242 | ​ |  | (15,256) | ​ |  | 14,986
Customer lists | ​ |  | 34,985 | ​ |  | (31,195) | ​ |  | 3,790
Total | ​ | $ | 107,489 | ​ | $ | (65,053) | ​ | $ | 42,436
​ Aggregate amortization expense for the three and nine-month periods ended September 30, 2022 was $12.1 million and $36.3 million, respectively. Aggregate amortization expense for the three and nine-month periods ended September 30, 2021 was $12.4 million and $37.3 million, respectively. ​ We evaluate long-lived assets, including amortizing intangible assets, for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. We perform the impairment analysis at the asset group for which the lowest level of identifiable cash flows is largely independent of the cash flows of other assets and liabilities. We determine the fair value of our amortizing assets based on estimated future cash flows discounted back to their present value using a discount rate that reflects the risk profiles of the underlying activities. During the nine-month period ended September 30, 2022, we identified indicators of impairment associated with certain acquired intangible assets based on our qualitative assessment, which led us to complete an interim quantitative impairment assessment. The primary indicator of impairment was our divestiture on April 30, 2022 of the STD Pharmaceutical Products Limited (“STD Pharmaceutical”) business acquired in our August 2019 acquisition of Fibrovein Holdings Limited. We recorded an impairment charge for the carrying value of $1.7 million of intangible assets during the nine months ended September 30, 2022, all of which pertained to our cardiovascular segment. ​ During the nine-month period ended September 30, 2021, we identified indicators of impairment associated with certain acquired intangible assets based on our qualitative assessment, which led us to complete an interim quantitative impairment assessment. During the nine-month period ended September 30, 2021, the primary indicator of impairment was our planned discontinuance of the Advocate™ Peripheral Angioplasty Balloon product line, sold under our license agreements with ArraVasc Limited (“ArraVasc”). We recorded an impairment charge for the remaining carrying value of ArraVasc intangible assets of approximately $1.6 million during the nine-month period ended September 30, 2021, all of which pertained to our cardiovascular segment. ​ Estimated amortization expense for developed technology and other intangible assets for the next five years consisted of the following as of September 30, 2022 (in thousands): ​
​ | ​ | ​ | ​
Year Ending December 31, |  | Estimated Amortization Expense
Remaining 2022 | ​ | $ | 12,121
2023 | ​ |  | 47,414
2024 | ​ |  | 44,330
2025 | ​ | ​ | 42,434
2026 | ​ |  | 31,860
​

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI https://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration